AU2010219463A1 - Protein kinase A and/or casein kinase II for alleviating the inhibition of neurite outgrowth - Google Patents

Protein kinase A and/or casein kinase II for alleviating the inhibition of neurite outgrowth Download PDF

Info

Publication number
AU2010219463A1
AU2010219463A1 AU2010219463A AU2010219463A AU2010219463A1 AU 2010219463 A1 AU2010219463 A1 AU 2010219463A1 AU 2010219463 A AU2010219463 A AU 2010219463A AU 2010219463 A AU2010219463 A AU 2010219463A AU 2010219463 A1 AU2010219463 A1 AU 2010219463A1
Authority
AU
Australia
Prior art keywords
nogo
kinase
cells
neurite outgrowth
ngr1
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2010219463A
Other languages
English (en)
Inventor
Yoshinori Takei
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medical Research Council
Original Assignee
Medical Research Council
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medical Research Council filed Critical Medical Research Council
Publication of AU2010219463A1 publication Critical patent/AU2010219463A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • C12N9/1211—Thymidine kinase (2.7.1.21)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
AU2010219463A 2009-03-06 2010-03-05 Protein kinase A and/or casein kinase II for alleviating the inhibition of neurite outgrowth Abandoned AU2010219463A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0903913.2A GB0903913D0 (en) 2009-03-06 2009-03-06 Compositions and methods
GB0903913.2 2009-03-06
PCT/GB2010/000391 WO2010100428A2 (en) 2009-03-06 2010-03-05 Compositions and methods

Publications (1)

Publication Number Publication Date
AU2010219463A1 true AU2010219463A1 (en) 2011-09-22

Family

ID=40600640

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2010219463A Abandoned AU2010219463A1 (en) 2009-03-06 2010-03-05 Protein kinase A and/or casein kinase II for alleviating the inhibition of neurite outgrowth

Country Status (10)

Country Link
US (1) US9089565B2 (OSRAM)
EP (1) EP2403515B1 (OSRAM)
JP (1) JP5670921B2 (OSRAM)
CN (1) CN102341117B (OSRAM)
AU (1) AU2010219463A1 (OSRAM)
CA (1) CA2750911A1 (OSRAM)
DK (1) DK2403515T3 (OSRAM)
ES (1) ES2493619T3 (OSRAM)
GB (1) GB0903913D0 (OSRAM)
WO (1) WO2010100428A2 (OSRAM)

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1066378A2 (en) 1998-04-03 2001-01-10 Curagen Corporation Lyst protein complexes and lyst interacting proteins
US6903187B1 (en) * 2000-07-21 2005-06-07 Allergan, Inc. Leucine-based motif and clostridial neurotoxins
WO2003027228A2 (en) * 2001-07-17 2003-04-03 Incyte Genomics, Inc. Receptors and membrane-associated proteins
JP2003093056A (ja) 2001-09-26 2003-04-02 Japan Science & Technology Corp ｐ５３のＳｅｒ４６をリン酸化する酵素
US20070025877A1 (en) 2003-06-03 2007-02-01 Hansen Christian M User interface for portable medical diagnostic apparatus and method of using the same
GB0314943D0 (en) * 2003-06-25 2003-07-30 Proteome Sciences Plc Screening methods
CN1849132A (zh) * 2003-09-10 2006-10-18 伦敦大学国王学院 调节神经元生长的化合物以及它们的用途
EP1695061A4 (en) * 2003-12-16 2008-02-20 Childrens Medical Center METHOD OF TREATING NEUROLOGICAL DISORDERS
US20050214288A1 (en) * 2004-03-26 2005-09-29 Human Genome Sciences, Inc. Antibodies against Nogo receptor
WO2006017673A2 (en) 2004-08-03 2006-02-16 Biogen Idec Ma Inc. Taj in neuronal function
US7414637B2 (en) * 2004-09-10 2008-08-19 Telmap Ltd. Placement of map labels
CA2684321A1 (en) 2007-03-21 2008-09-25 Effat Emamian Compositions comprising pkac fragments and uses thereof for inhibiting akt1, p70s6k or abl activity

Also Published As

Publication number Publication date
WO2010100428A2 (en) 2010-09-10
DK2403515T3 (da) 2014-08-11
HK1166017A1 (en) 2012-10-19
ES2493619T3 (es) 2014-09-12
GB0903913D0 (en) 2009-04-22
US9089565B2 (en) 2015-07-28
US20110318326A1 (en) 2011-12-29
CN102341117B (zh) 2015-01-21
JP5670921B2 (ja) 2015-02-18
CA2750911A1 (en) 2010-09-10
EP2403515B1 (en) 2014-05-21
CN102341117A (zh) 2012-02-01
EP2403515A2 (en) 2012-01-11
WO2010100428A3 (en) 2010-10-21
JP2012519676A (ja) 2012-08-30

Similar Documents

Publication Publication Date Title
Yang et al. Ser1928 is a common site for Cav1. 2 phosphorylation by protein kinase C isoforms
Llorens et al. Developmental analysis of Lingo‐1/Lern1 protein expression in the mouse brain: interaction of its intracellular domain with Myt1l
Klann et al. Increased phosphorylation of a 17‐kDa protein kinase C substrate (P17) in long‐term potentiation
Tanga et al. The PTN‐PTPRZ signal activates the AFAP1L2‐dependent PI3K‐AKT pathway for oligodendrocyte differentiation: targeted inactivation of PTPRZ activity in mice
US20070054848A1 (en) Composition and method for nerve regeneration
Li et al. Akt-phosphorylated mitogen-activated kinase-activating death domain protein (MADD) inhibits TRAIL-induced apoptosis by blocking Fas-associated death domain (FADD) association with death receptor 4
CN102100913B (zh) 脑损伤治疗的靶点和药物
Calderilla‐Barbosa et al. Phosphorylation of dystrophin Dp71d by Ca2+/calmodulin‐dependent protein kinase II modulates the Dp71d nuclear localization in PC12 cells
Denes et al. The neuroprotective peptide PACAP1-38 contributes to horizontal cell development in postnatal rat retina
Takei Phosphorylation of Nogo receptors suppresses Nogo signaling, allowing neurite regeneration
US9089565B2 (en) Compositions and methods for causing neurite outgrowth
US20170173053A1 (en) Method of Modulating Protein 14-3-3 Functionality By Facilitating or Inhibiting Phosphorylation
HK1166017B (en) Compositions and methods for causing neurite outgrowth
Cozzi et al. Density of peptide histidine‐isoleucine‐and vasoactive intestinal peptide‐immunoreactive nerve fibers in the sheep pineal gland is not affected by superior cervical ganglionectomy
JP7576335B2 (ja) Ｃｌｓｐ阻害物質による影響を受けないｃｌｓｐ誘導体及びｃｌｓｐ活性の増強／保護剤
Hartmann Wnt signaling in cartilage development
Kim The GSL-Dependent Signaling
Scott The role of p75NTR in axonal regeneration and intraspinal plasticity following spinal deafferentation
WO2006075172A2 (en) Methods for identifying compounds capable of modulating cftr/ck2 interaction and/or cftr phosphorylation by ck2
Lee The Functions of Atypical PKC and the PAR Complex in Axon Growth Inhibition
Cadieux Molecular mechanisms of myelin-associated glycoprotein (MAG)-and Nogo-induced Smad2 phosphorylation
Koraishy The crosstalk of Hgf and canonical Wnt signaling in kidney repair
Alabed The role of RhoA interacting proteins in the Nogo signalling pathway of axon outgrowth inhibition
Perdigoto Mechanisms of neurite outgrowth inhibition by Myelin-associated glycoprotein
Hsieh Regulation of actin-depolymerizing factor cofilin in response to Nogo-66

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application